UnknownPhase 4

Intra-nasal Dexmedetomidine for Children Undergoing MRI Imaging

180 participantsStarted 2019-02

Plain-language summary

This study aims to assess the use of intranasal dexmedetomidine (IN-dex) as a sole agent in aiding the successful completion of a MRI scans in children. Dexmedetomidine, a routinely used anesthetic agent in our institution, has many benefits including sedation with neuro-protective and respiratory sparing features. We will test its effectiveness in completing MRI scans in children that would otherwise be given a full general anesthetic.

Who can participate

Age range3 Years – 18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * ASA 1 or 2 * Scheduled for elective MRI scan on the general anesthesia list * Child Life MRI simulation score of 6-10 (Figure 1) * Age 3 - 18 Exclusion Criteria: * Taking existing opioid, sedative, or cannabinoid medication * Severe learning disability defined as the inability to follow simple commands * Severe Cardiac disease * Chronic hypertension * Allergy to dexmedetomidine * Nasal anatomical abnormality * Known or anticipated difficult airway

What they're measuring

Dose

Timeframe: Immediately after completion of the MRI scan.

Trial details

NCT IDNCT03806777

SponsorUniversity of British Columbia

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-03

Contact for this trial

Andrew K Poznikoff, BSc

604-875-2000 andrew.poznikoff@cw.bc.ca

View on ClinicalTrials.gov More MRI Sedation trials